Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Approves Opdivo for Head and Neck Cancer

Bristol-Myers Squibb Co.’s immuno-oncology treatment Opdivo has now been approved in five tumor types in under two years by the U.S. FDA.

Read More »

White House says Obamacare enrollment a priority

Getting more Americans to enroll for health insurance under President Barack Obama’s healthcare law known as Obamacare is a top priority of his administration until President-elect Donald Trump takes office, the White House said.

Read More »

U.S. DEA temporarily bans synthetic opioid ‘pink’ after 46 deaths

The U.S. Drug Enforcement Administration (DEA) said it had temporarily categorized a synthetic opioid nicknamed “pink” as a dangerous drug, after receiving at least 46 reports of deaths associated with its use.

Read More »

Zika striking women at higher rates than men

Adult women in Puerto Rico were significantly more likely to develop Zika than men, researchers said, raising new questions about the potential role of sexual transmission of the virus from males to females.

Read More »

Despite progress, measles kills 400 children a day: WHO

The number of deaths from measles has fallen by 79 percent worldwide since 2000 – due mainly to mass vaccination campaigns – but nearly 400 children still die from the disease every day, global health experts said.

Read More »

Cosmo shares jump on colonoscopy trial results

Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.

Read More »

Bristol-Myers’ Opdivo succeeds in key stomach cancer study

Bristol-Myers Squibb Co. said its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.

Read More »

Struggling Novavax Pink Slips 30% of Workforce and Retools Pipeline After Trial Flop

In the wake of a failed Phase III clinical trial, Gaithersberg, Md.-based Novavax announced that it plans to cut 30 percent of staff and restructure the company.

Read More »

Bristol-Myers Squibb Slams Down $100 Million to Make a Play Into NASH

Competition is getting tighter in the market to treat non-alcoholic steatohepatitis (NASH). Bristol-Myers Squibb struck a $100 million deal with Osaka, Japan-based Nitto Denko Corp. for rights to that company’s Phase Ib therapy.

Read More »

Scientists develop new HIV test on USB stick

Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient’s blood.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom